Sugi Predict

Sugi Predict / Compounds / SCHEMBL5275535

SCHEMBL5275535

SCHEMBL5275535

C#CC1CCN1C(=O)OC(C)(C)C

nearest known ligand 0.49

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ HSD17B10 Q99714 1/20 0.47
▸ HPGD P15428 1/20 0.43
▸ CTSK P43235 1/20 0.41
▸ RECQL P46063 1/20 0.41
▸ CHRM2 P08172 1/20 0.40
▸ CHRM1 P11229 1/20 0.40
▸ CHRM3 P20309 1/20 0.40
▸ MEN1 O00255 1/20 0.40
▸ ALDH1A1 P00352 1/20 0.40
▸ MAPT P10636 1/20 0.40
▸ KMT2A Q03164 1/20 0.40
▸ SMN1; SMN2 Q16637 2/20 0.39
▸ USP2 O75604 1/20 0.39
▸ EPHX1 P07099 1/20 0.38
▸ PTPN2 P17706 1/20 0.38
▸ PTPN1 P18031 1/20 0.38
▸ PTPN6 P29350 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4919669 1.00 HSD17B10 (0.47) HSD17B10HPGDCTSKRECQLCHRM2
SCHEMBL3188564 0.90 HSD17B10 (0.55) HSD17B10HPGDCTSKRECQLMEN1
SCHEMBL231219 0.90 HSD17B10 (0.55) HSD17B10HPGDCTSKRECQLMEN1
SCHEMBL889059 0.90 HSD17B10 (0.55) HSD17B10HPGDCTSKRECQLMEN1
SCHEMBL15317053 0.89 HPGD (0.50) HSD17B10HPGDCTSKRECQLMEN1
SCHEMBL525478 0.89 HPGD (0.50) HSD17B10HPGDCTSKRECQLMEN1
SCHEMBL10082580 0.89 HPGD (0.50) HSD17B10HPGDCTSKRECQLMEN1
SCHEMBL9554546 0.84 CTSK (0.42) HSD17B10HPGDCTSKRECQLCHRM2
SCHEMBL6166916 0.83 CTSK (0.49) HSD17B10CTSKCHRM2CHRM1CHRM3
SCHEMBL16067363 0.83 CTSK (0.49) HSD17B10CTSKCHRM2CHRM1CHRM3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250340548-A1 KRAS G12C INHIBITORS FRONTIER MEDICINES CORP (US) 2025-11-06 — — US disclosed
US-12291539-B2 KRAS G12C inhibitors FRONTIER MEDICINES CORPORATION (US) 2025-05-06 — — US disclosed
US-20250136586-A1 Substituted 7-(Pyrimidin-4-yl)Quinolin-4(1H)-One Compounds as Cyclin Dependent Kinase Inhibitors BEIGENE, LTD. (KY) 2025-05-01 — — US disclosed
WO-2025051148-A1 NITROGEN-CONTAINING HETEROARYL COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF 北京鞍石生物科技股份有限公司 2025-03-13 — — WO disclosed
EP-4514797-A1 SUBSTITUTED 7- (PYRIMIDIN-4-YL) QUINOLIN-4 (1H) -ONE COMPOUNDS AS CYCLIN DEPENDENT KINASE INHIBITORS BeiGene, Ltd. (KY) 2025-03-05 — — EP disclosed
US-20250025443-A1 COMPOUNDS AND METHODS FOR TREATING CORONA VIRUSES Clear Creek Bio, Inc. (US) 2025-01-23 — — US disclosed
CN-119320383-A Nitrogen-containing heteroaryl compound, and preparation method and application thereof 北京鞍石生物科技股份有限公司 2025-01-17 — — CN disclosed
US-20250019387-A1 KRAS G12C INHIBITORS FRONTIER MEDICINES CORPORATION 2025-01-16 — — US disclosed
CN-119053598-A Substituted 7- (pyrimidin-4-yl) quinolin-4 (1H) -one compounds as cyclin dependent kinase inhibitors 百济神州有限公司 2024-11-29 — — CN disclosed
EP-4426695-A1 KRAS G12C INHIBITORS Frontier Medicines Corporation (US) 2024-09-11 — — EP disclosed
WO-2023208172-A1 SUBSTITUTED 7- (PYRIMIDIN-4-YL) QUINOLIN-4 (1H) -ONE COMPOUNDS AS CYCLIN DEPENDENT KINASE INHIBITORS BEIGENE , LTD. (KY) 2023-11-02 — — WO disclosed
WO-2023081840-A1 KRAS G12C INHIBITORS FRONTIER MEDICINES CORPORATION (US) 2023-05-11 — — WO disclosed
WO-2023081840-A1 KRAS G12C INHIBITORS FRONTIER MEDICINES CORPORATION (US) 2023-05-11 — — WO disclosed
WO-2023064493-A1 COMPOUNDS AND METHODS FOR TREATING CORONAVIRUSES Clear Creek Bio, Inc. (US) 2023-04-20 — — WO disclosed
WO-2023064493-A1 COMPOUNDS AND METHODS FOR TREATING CORONAVIRUSES Clear Creek Bio, Inc. (US) 2023-04-20 — — WO disclosed
EP-1863797-A1 2-AZETIDINYL-4-(lH-PYRAZOL-3-YLAMINO)PYRIMIDINES AS INHIBITORS OF INSULIN-LIKE GROWTH FACTOR-I RECEPTOR ACTIVITY AstraZeneca AB (SE) 2007-12-12 — — EP disclosed
WO-2006100461-A1 2-AZETIDINYL-4-(lH-PYRAZOL-3-YLAMINO)PYRIMIDINES AS INHIBITORS OF INSULIN-LIKE GROWTH FACTOR-I RECEPTOR ACTIVITY ASTRAZENECA AB (SE) 2006-09-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250136586-A1 Substituted 7-(Pyrimidin-4-yl)Quinolin-4(1H)-One Compounds as Cyclin Dependent Kinase Inhibitors CDK4, CDK7, CDK8 HSD17B10 3479/4885HPGD 1486/4885CTSK 1395/4885
US-12291539-B2 KRAS G12C inhibitors KRAS, NRAS, HRAS HSD17B10 4044/4885HPGD 1613/4885CTSK 1881/4885
US-20250340548-A1 KRAS G12C INHIBITORS KRAS, NRAS, HRAS HSD17B10 4044/4885HPGD 1613/4885CTSK 1881/4885
US-20250019387-A1 KRAS G12C INHIBITORS KRAS, NRAS, HRAS HSD17B10 4044/4885HPGD 1613/4885CTSK 1881/4885
US-20250025443-A1 COMPOUNDS AND METHODS FOR TREATING CORONA VIRUSES ACE, PREP, PEPD HSD17B10 2712/4885HPGD 2322/4885CTSK 93/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.